Type 1 fimbrial adhesin FimH (FimH)

Type 1 fimbrial adhesin FimH is a lectin protein located at the distal tip of type 1 fimbriae (pili) in Escherichia coli and other Enterobacteriaceae [13, 18]. Its primary biological function is to mediate the specific, mannose-sensitive attachment of bacteria to host cell surfaces by binding to mannosylated glycoproteins, such as Uroplakin Ia in the urinary tract or CEACAM6 in the intestinal mucosa [2, 9]. This adhesion is a critical first step in the pathogenesis of urinary tract infections (UTIs) and contributes to the persistence of adherent-invasive E. coli (AIEC) in the gut of patients with Crohn's disease [3, 22]. FimH is also increasingly recognized for its role in enabling colibactin-producing E. coli to adhere to the colonic epithelium, potentially promoting DNA damage and colorectal carcinogenesis [1, 17]. Therapeutically, FimH is targeted using anti-adhesion strategies, primarily small-molecule mannoside antagonists like sibofimloc [1, 9]. These drugs competitively occupy the FimH mannose-binding pocket, preventing bacterial attachment and allowing the pathogens to be naturally cleared from the body without exerting the direct bactericidal pressure that drives antibiotic resistance [4, 19]. Clinical development of FimH inhibitors is ongoing for the treatment of recurrent UTIs and for maintaining remission in Crohn's disease patients [2, 23].

Other names

FimH lectinMannose-binding adhesinE. coli adhesion proteinType 1 pilus adhesinProtein FimH

FimH antagonists competitively bind to the mannose-binding pocket of the FimH lectin domain, preventing the bacteria from adhering to mannosylated glycoproteins on host cell surfaces [2, 9].